In vivo characterization of heteronuclear platinum (II) ruthenium (III) complexes on human lung adenocarcinoma cells.
Date of Submission
Project Advisor 1
Cancer is one of the leading causes of death worldwide. Scientists have researched the characteristics of mixed metal compounds and their applications in the treatment of cancer. Mononuclear metal compounds, such as cisplatin and NAMI-A, have been very successful at killing and even inhibiting the metastatic potential of cancer cells. By synthesizing heteronuclear compounds that take advantage of the cytotoxic nature of platinum centers and the anti-metastatic properties of ruthenium, AH197 and IT127 were characterized in vivo on A549 cells. The characterization revealed that AH197 is 10x more effective at inhibiting the motility of the human lung adenocarcinoma cells when compared to NAMI-A, a ruthenium centered compound in clinical trials for use against metastatic cancers. The compounds were not shown to be more cytotoxic than cisplatin, but were comparable. Continuing to work on characterizing the compounds, and testing on other cancer cell types, could reveal components of these compounds or metal centers that could be used to help treat this difficult and devastating disease.
Access restricted to On-Campus only
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Philpott, Jessica, "In vivo characterization of heteronuclear platinum (II) ruthenium (III) complexes on human lung adenocarcinoma cells." (2012). Senior Projects Spring 2012. 290.
This work is protected by a Creative Commons license. Any use not permitted under that license is prohibited.Bard Off-campus Download
Bard College faculty, staff, and students can login from off-campus by clicking on the Off-campus Download button and entering their Bard username and password.